BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)
February 23, 2015 12:28 PM ESTPTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.
$BMRN is interested in buying $PTCT? Thats hard to believe.
— Adam Feuerstein (@adamfeuerstein) February 23, 2015... More
UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters
February 23, 2015 12:03 PM EST(Updated - February 23, 2015 12:43 PM EST)
PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.
According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More
BioMarin Pharma (BMRN) Announces Granting of 91.6k RSUs
February 23, 2015 6:52 AM ESTBioMarin Pharma (NASDAQ: BMRN) announced that on February 17, 2015, the compensation committee of BioMarin's board of directors approved the grant to 125 newly hired employees of 91,610 restricted share units in the aggregate and stock options to purchase 35,400 shares of common stock in the aggregate. A portion of these grants are special inducement grants to certain employees of... More
